This entry was posted on Monday, April 11th, 2011 at 3:50 am and is filed under 44

Related posts brought to you by Yet Another Related Posts Plugin.

NEW YORK, April 4, 2011 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue:

Alzheimer disease – New drugs, markets and companies

http://www.reportlinker.com/p0203533/Alzheimer-disease—New-drugs-markets-and-companies.html

Alzheimer’s disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

Early diagnosis of Alzheimer’s disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.

The current management of Alzheimer’s disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer’s disease is being recognized.

Research in Alzheimer’s disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer’s disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Over 175 clinical trials are listed, of which 125 are still in progress and 50 were discontinued for various reasons.

Alzheimer’s disease market in the seven major markets is analyzed for the year 2010. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2020. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 141 companies involved in developing diagnostics and therapeutics for Alzheimer’s disease are presented along with 107 collaborations. The bibliography contains over 600 publications that are cited in the report.The report is supplemented with 43 tables and 14 figures.

Table of contents

Clinical features, epidemiology and pathology of Alzheimer disease

Diagnostic procedures for Alzheimer’s disease

Management of Alzheimer’s disease

Research in Alzheimer’s disease

Drug discovery and development for Alzheimer’s disease

Marketing and financial aspects of Alzheimer’s disease

To order this report:

: Alzheimer disease – New drugs, markets and companies

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Foundation started to assist seniors groups

Cerritos-based CareMore has established The CareMore Foundation, a nonprofit foundation to grant funds, resources and recognition to local senior-focused community organizations.

“There are many unmet critical health needs for seniors that go unaddressed due to a lack of resources at the community level,” said Leeba Lessin, president of CareMore and the architect of the creation of the Foundation. “The Foundation’s focus will be to identify and support those charitable organizations which are dedicated to improving the quality of life for all seniors.”

The foundation’s first project for 2011 will focus on addressing senior hunger, a major social issue for seniors in many communities.

The CareMore Foundation is currently calling for grants from senior-focused, community-based not-for profit organizations that have a direct or indirect influence on the issues of senior hunger and nutrition. The Foundation’s Advisory Committee will review all grant applications and funds will be awarded based on a priority basis for those who can demonstrate their role in helping seniors improve their quality of life with nutritional resources.

WOMEN HELPING WOMEN

Farmers & Merchants bank executive is honored: Christine Walker, vice president of Long Beach-based Farmers & Merchants Bank, was honored at “The Star Within” – Women Helping Women’s first evening gala

April 1 at the Newport Beach Marriott.

A fifth-generation banking executive, Walker began learning her family’s business after graduating from college, working on the front lines as a teller. Today, Walker serves the Farmers & Merchants organization in leadership roles. In addition to being bank vice president, Walker is chief risk officer at the trust company, and additionally plays a management role with the Walker family holdings involving commercial leasing and real estate development.

Warehouse, manufacturing facility sold for $8.1 million: A 120,000-square-foot warehouse and manufacturing facility in Rancho Dominguez was sold to Agron Inc. for about $8.1 million, according to Grubb & Ellis Co.

Built in 1973, 2060 E. Via Arado is a free-standing facility on approximately 5 acres.

Jerry Gillman, senior vice president, and Chuck Berger, senior associate, Industrial Group, represented 2060 E. Via Arado Property Co. in the sale. Brad Levin of DAUM Commercial Real Estate Services represented Agron in the transaction.

– From staff reports

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

The Georgia legislative session has just three days remaining. But for people like Fred Brown and Mignon Fleishel, it will be an agonizing countdown.

They each have an elderly mother living in a Kennesaw assisted living facility. Both women have dementia and need help with mobility.

Brown and Fleishel want their mothers to remain at DayBreak Village – where they are happy — and not be forced to live in a nursing home.

A bill that would help their parents stay there has passed the state Senate, but is stuck in the House – the apparent victim in a political tug-of-war between the two chambers.

Senate Bill 178 would allow Georgia assisted living facilities to hire certified medication aides to help residents in taking their prescriptions. It would also give the facilities more flexibility in dealing with residents who need help in getting around, like Brown’s and Fleishel’s mothers.

Brown says he’s frustrated by the legislative bottleneck. He doesn’t want the assisted living bill to wait another year before passage. “I don’t know whether my mother will last another year,’’ he says. “She’ll soon be 89.’’

Currently, if an assisted living resident is considered non-ambulatory, the state requires that person to be discharged – often moving to a nursing home – unless the state grants a waiver. And there are restrictions on what medication help is permitted.

The Senate bill would create a new category for assisted living facilities of at least 25 beds that serve only private-pay patients. Currently the state lists just two classifications of long-term care facilities: nursing facilities and personal care homes (which now include assisted living).

But with the Legislature not convening again for another week – and with just three days left for bills to pass — the wait continues for hundreds of families, says Kathy Floyd, associate state director for advocacy at AARP Georgia.

Such legislation in past years has been stymied by the nursing home industry. But this year the Georgia Health Care Association, which represents nursing homes, has agreed to the assisted living changes. Patients who require around-the-clock care would still end up in nursing homes.

Consumer advocates ‘’have waited on this for 16 years,’’ Floyd says. “We don’t want to wait another year.’’

“This is a consumer choice issue,’’ she says. Families want their loved ones to ‘’age in place,’’ she adds.

The bill has stalled in the House Rules Committee, with sponsors so far unable to pry it loose.

“What you see always in the Legislature is horse-trading between the two bodies,’’ Floyd says. “Unfortunately, this bill has been caught up in that.’’

If Senate Bill 178 gets to the House floor, it will pass easily, Floyd says.

Fleishel points out that changing the state rules will help a ‘’tidal wave’’ of older Georgia residents. “We have so many people aging,’’ she says.

She says her mother ‘’is thriving’’ at DayBreak Village.

Brown says his mother-in-law was forced to go to a nursing home a year ago and died there. He doesn’t want his own mother to move. “It’s very important that she live with dignity.’’

The legislative impasse leaves his mother’s situation in limbo, Brown says. “I would sure hate for the ball to be dropped now.’’

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

The Alzheimer’s Association, Northwest Ohio Chapter, is hosting several family and community education programs in March. Programs are held at the Alzheimer’s Association, 2500 North Reynolds Road, Toledo, OH.

HBO’s “The Alzheimer’s Project: Momentum in Science”
Thursday, March 10, 4 pm. to 5:30 p.m.
Amidst the heartbreak of Alzheimer’s there is real reason to hope. This documentary takes viewers into the laboratories and clinics of 25 leading scientists and physicians who seek to discover what can be done to better detect and diagnose Alzheimer’s, delay the onset of memory loss, affect the brain changes associated with the disease, and ultimately, prevent Alzheimer’s altogether. The film delves into the intriguing links to heart disease and diabetes, as well as the potential benefits of exercise and diet.

HBO’s “The Alzheimer’s Project: Grandpa, Do you Know Who I Am?”
Thursday, March 17, 4 pm. to 5:30 p.m.
This HBO film tells five stories of children, ages 6 to 15, who are coping with grandparents living with Alzheimer’s disease. Maria Shriver, whose own father had the disease, provides commentary and delivers valuable communication and care lessons.

“Who is He (She) Now? Caregiving in the Late Stage and End of Life”
Tuesday, March 22, 4 p.m. to 5:30 p.m.
This program is designed for family caregivers and explores topics such as late stage changes in the person, practical caregiving techniques, visiting, coping with caregiver grief, ethical and medical decisions, and how to know when to call in a hospice. Co-sponsored with Odyssey Hospice.

“Caregiving Wellness: Applying Lessons in Mindfulness to Everyday Care”
Thursday, March 24, 6:30 to 8:30 p.m.
The program looks at wellbeing from a spiritual, physical and emotional viewpoint and its importance in being an effective, healthy caregiver. Participants will learn practical ways to cope with stress and maintain or regain wellness.

The programs are free, but registration is requested. To register, call the Alzheimer’s Association at 419.537.1999 or 1-800.272.3900.

Download Word DOC

Julianne Jardine

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Posted by:janinsanfran

A note of caution, please, for this discussion: without the new test, all clinical diagnoses of Alzheimer’s disease are categorized as “possible” or “probable.”

Although Alzheimer’s is said to be the most common form of dementia, there are others with differing manifestations – although none are good for you, if I’m not being too flip.

As janinsanfran notes, this is a rapidly-changing field with new information coming along all the time. Let’s be careful with the claims we post here.

Posted by:Ronni Bennett

P.S. The clinic that diagnosed my husband based its diagnostic success rate on clinical diagnosis PLUS brain autopsy.

Posted by:SuzyR |Thursday, 27 January 2011 at 10:29 AM

We had a brain autopsy done on my Mom, too. Medication made a very significant difference in her functioning ability, from cognition and mood to her ability to swallow.

We did it at the suggestion of her neurologist. He told us, “Right now, we’re treating everyone with dementia pretty much the same way. But by the time you are her age, we might have different treatments based on the diseases. If you find out what she has when she dies, it might help you, in time.”

My sister & I knew that my mother would be willing to do *anything* for us, so we asked for the autopsy. Trying to keep track of where her body was over the weekend – I get chills remembering that.

Posted by:mary jamison |Thursday, 27 January 2011 at 11:12 AM

Being 57 and still required to be in the work force for easily another 15 years, I would not chance announcing my candidacy for mental illness. Finding and keeping a job with the age stigma is hard enough. I would like to know, though, for the sake of those whom my care will eventually befall. In fact, I am just assuming I will get it eventually. I call it my personal enemy, do everything I can to strengthen myself against it and hope for the research findings for a cause.

I cared for my mother for two and a half years sleeping outside her door on a couch while she struggled with dementia early in the last decade. Her most terrifying moments were her lucid ones. Trapped and suffering. My experience was similar to SuzyR and I agree that taking care of legal business is the best preparation one can give to one’s loved ones who will have to assist us should we find ourselves in this living death. I’m re-committing to doing just that after reading this post and comments.

People who have not had to give direct care really have no idea how devastating this disease is (and I would wish this task on no one). My children have no idea and I worry for their future with me.

Posted by:Cile

I’d want to know. Like the others here, I would:

1) Get rid of even more stuff.
2) Get the best possible legal advice and preparation.
3) Relax and enjoy what’s left.

These are all things, for that matter, that I ought to be doing anyway!

Posted by:Paula |Thursday, 27 January 2011 at 12:09 PM

Today’s issue of Alzheimer’s Daily News

Posted by:June Calender

I’m with the responders who find this development interesting but would not be first in line to be tested. At 74 I’m still working and functioning within a normal range (aside from forgetting where I put my car keys or coffee cup sometimes). Since there’s no really effective treatment and no cure, why would I want yet one more thing to worry about? My husband (81 with no signs of AD) and I put our legal affairs in order many years ago, with updates as needed.